Showing 1381-1390 of 1535 results for "".
- Galderma Gives Chefs a Hand with New Excipial Partnershiphttps://practicaldermatology.com/news/galderma-gives-chefs-a-hand-with-new-excipial-partnership/2458582/Galderma Laboratories, L.P., maker of Excipial, is teaming up with the American Culinary Federation to help chefs treat their dry hands. Professional chefs spend about 14 hours a day in the kitchen, prepping food and washing their hands,
- Largest Independent US Psoriasis Registry to Track Safety of Ixekizumab Biologic Treatmenthttps://practicaldermatology.com/news/largest-independent-us-psoriasis-registry-to-track-safety-of-ixekizumab-biologic-treatment/2458583/The Corrona Psoriasis Registry will track the drug safety reporting for ixekizumab, Eli Lilly and Company's biologic medication that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation
- Vitiligo and Gray Hair Treatment Breakthrough? Study IDs Mechanism That Controls Skin and Hair Colorhttps://practicaldermatology.com/news/vitiligo-and-gray-hair-treatment-breakthrough-study-ids-mechanism-that-controls-skin-and-hair-color/2458587/A pair of molecular signals controls skin and hair color in mice and humans - and could be targeted by new drugs to treat skin pigment disorders like vitiligo, according to a report out of NYU Langone Medical Center in New York City. Finding ways to activate these pathways could lea
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- FDA Approves Inflectra, a Biosimilar to Remicadehttps://practicaldermatology.com/news/fda-approves-inflectra-a-biosimilar-to-remicade/2458618/And then there were two ... The U.S. Food and Drug Administration approved the biosimilar Inflectra (infliximab-dyyb) for multiple indications. Inflectra is biosimilar to Janssen Biotech, Inc.&rsq
- Next Stop FDA Approval? Dupilumab Improves Symptoms in Moderate-to-Severe ADhttps://practicaldermatology.com/news/next-stop-fda-approval-dupilumab-improves-symptoms-in-moderate-to-severe-ad/2458625/Dupilumab helps improve the signs and symptoms of moderate-to-severe atopic dermatitis (AD) in adults, according to two late stage clinical trials. The U.S. Food and Drug Administration (FDA) granted dupilumab Breakthrough Therapy designation in AD in November 2014. U.S. regulatory
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via
- Do the FDA's Proposed Regulations on Tanning Bed Use Go Far Enough?https://practicaldermatology.com/news/do-the-fdas-proposed-regulations-on-tanning-bed-use-go-far-enough/2458646/As the comment period on the US Food and Drug Administration’s proposal to restrict tanning bed use winds down, researchers are weighing in on the proposal's merits and potential shortfalls. Investigators
- Vitiligo Working Group Launches Public Awareness Campaignhttps://practicaldermatology.com/news/vitiligo-working-group-launches-public-awareness-campaign/2458665/The Vitiligo Working Group is drawing attention to the many faces of vitiligo with a new public awareness campaign. This initiative rolls out at the 74th Annual Meeting of the American Academy of Dermatology (AAD) in Washington, DC.